Patients with histologically confirmed stage IV NSCLC were randomized 2 : 1 to receive gemcitabine ( 1250 mg/m ( 2 ) , days 1/8 ) and cisplatin ( 75 mg/m ( 2 ) , day 1 ) with [ gemcitabine/cisplatin/iniparib ( GCI ) ] or without [ gemcitabine/cisplatin ( GC ) ] iniparib ( 5.6 mg/kg , days 1/4/8 / 11 ) every 3 weeks for six cycles .